Survival data on the use of cisplatin and pemetrexed as adjuvant chemotherapy for early-stage non-small cell lung cancer (NSCLC) after complete tumor resection has been provided for the first time by investigators in Germany.
The investigators conducted the randomized Phase II TREAT study to test the hypothesis that a regimen with reduced toxicity might make postoperative delivery of adjuvant chemotherapy drugs to NSCLC patients more feasible and, thus, increase compliance and survival.